BioNTech (NASDAQ:BNTX) Price Target Raised to $143.00

by · The Cerbat Gem

BioNTech (NASDAQ:BNTX – Get Free Report) had its price target boosted by BMO Capital Markets from $130.00 to $143.00 in a report issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. BMO Capital Markets’ price target would indicate a potential upside of 35.74% from the stock’s previous close.

Several other analysts have also recently weighed in on the company. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. HC Wainwright restated a “buy” rating and set a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. Truist Financial began coverage on BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price target on the stock. Berenberg Bank began coverage on BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective for the company. Finally, Wells Fargo & Company started coverage on shares of BioNTech in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price on the stock. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $144.03.

View Our Latest Analysis on BioNTech

BioNTech Price Performance

Shares of BioNTech stock opened at $105.35 on Tuesday. The business has a 50 day moving average of $116.76 and a 200 day moving average of $113.06. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a market cap of $25.26 billion, a PE ratio of -50.17 and a beta of 0.30. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX – Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.90 EPS. As a group, equities research analysts forecast that BioNTech will post -3.88 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp raised its holdings in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 246 shares during the last quarter. Planning Capital Management Corp grew its position in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after purchasing an additional 450 shares during the period. Quintet Private Bank Europe S.A. raised its stake in BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after buying an additional 700 shares during the last quarter. Allianz SE bought a new position in shares of BioNTech during the 4th quarter valued at $90,000. Finally, GAMMA Investing LLC boosted its stake in shares of BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after buying an additional 300 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

(Get Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Featured Stories